北京基因型耐多药结核分枝杆菌二线抗结核药物耐药基因突变特征分析

doi:10.19485/j.cnki.issn2096-5087.2021.10.003

预防医学

2021, Vol. 33

Issue (10): 983-987 DOI: 10.19485/j.cnki.issn2096-5087.2021.10.003

论著

本期目录 | 过刊浏览 | 高级检索

北京基因型耐多药结核分枝杆菌二线抗结核药物耐药基因突变特征分析

叶静芬¹, 方晴¹, 胡耀仁¹, 许小敏¹, 车洋²

1.中国科学院大学宁波华美医院感染科,浙江宁波 315010;
2.宁波市疾病预防控制中心结核病防制所

Second-line drug resistance associated mutations in multidrug-resistant Mycobacterium tuberculosis Beijing genotype strains

YE Jingfen^*, FANG Qing, HU Yaoren, XU Xiaomin, CHE Yang

^*Department of Infection, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang 315010, China

摘要
参考文献
相关文章
Metrics

全文: PDF(849 KB)
输出: BibTeX | EndNote (RIS)

摘要目的了解耐多药结核分枝杆菌（MDR-TB）北京基因型菌株对二线抗结核药物的耐药情况及耐药基因突变特征。方法对中国科学院大学宁波华美医院2017—2019年临床分离的MDR-TB采用RD105缺失基因检测法鉴定基因型。采用药敏试验比例法检测MDR-TB对卡那霉素、阿米卡星、卷曲霉素、氧氟沙星和左氧氟沙星等二线抗结核药物的耐药性。以结核分枝杆菌标准株H₃₇RV为参比序列,PCR法检测rrs、tlyA、eis、gidB、gyrA和gyrB耐药基因突变,通过比较不同基因型的耐药率和基因突变率,分析北京基因型二线抗结核药物耐药特征。结果 133株MDR-TB经鉴定,北京基因型106株,非北京基因型27株。北京基因型MDR-TB卡那霉素、阿米卡星、卷曲霉素、氧氟沙星和左氧氟沙星耐药率分别为9.43%、7.55%、3.77%、32.08%和32.08%,准广泛耐药率为30.19%,广泛耐药率为7.55%,与非北京基因型比较差异均无统计学意义（P>0.05）。北京基因型MDR-TB rrs、tlyA、eis、gidB、gyrA和gyrB突变率分别为7.55%、7.55%、1.89%、2.83%、36.79%和2.83%,与非北京基因型比较差异均无统计学意义（P>0.05）。rrs突变类型有2种,tlyA 1种,eis 2种,gidB 2种,gyrA 5种,gyrB 3种,均以点突变为主。结论北京基因型菌株为MDR-TB的优势菌株,对氟喹诺酮类药物耐药率较高,以gyrA基因突变为主。

	服务

	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	叶静芬
	方晴
	胡耀仁
	许小敏
	车洋

关键词 ：结核分枝杆菌, 北京基因型, 耐药, 基因突变

Abstract：Objective To learn the characteristics of second-line drug resistance and related gene mutations of multidrug-resistant Mycobacterium tuberculosis ( MDR-TB ) Beijing genotype strains. Methods The MDR-TB isolates in Hwa Mei Hospital from 2017 to 2019 were enrolled and detected using RD105 deletion-targeted multiplex polymerase chain reaction (PCR). The proportion method for drug susceptibility test was used to detect the drug-resistant profiles against kanamycin, amikacin, capreomycin, ofloxacin and levofloxacin. The gene sequencing of rrs, tlyA, eis, gidB, gyrA and gyrB was conducted by PCR compared with H₃₇RV strain. The differences in the rates of drug resistance and mutation between Beijing and non-Beijing genotype strains were examined to understand the characteristics of Beijing genotype strains. Results There were 106 Beijing genotype and 27 non-Beijing genotype strains in 133 MDR-TB isolates. The drug resistance rates of kanamycin, amikacin, capreomycin, ofloxacin and levofloxacin in Beijing genotype strains were 9.43%, 7.55%, 3.77%, 32.08% and 32.08%, respectively. The rates of quasi-extensive and extensive drug resistance in Beijing genotype strains were 30.19% and 7.55%. The gene mutation rates of rrs, tlyA, eis, gidB, gyrA and gyrB in Beijing genotype strains were 7.55%, 7.55%, 1.89%, 2.83%, 36.79% and 2.83%, respectively. There were no significantly differences between Beijing and Non-Beijing genotype strains in the factors above ( P>0.05 ). The gene rrs, tlyA, eis, gidB, gyrA and gyrB had 2, 1, 2, 2, 5 and 3 mutation types, respectively, with single base substitution as the main type. Conclusion Beijing genotype strains are dominant in MDR-TB, with high resistance to fluoroquinolones and mainly gyrA gene mutation.

Key words： Mycobacterium tuberculosis Beijing genotype drug resistance mutation

收稿日期: 2021-09-03 出版日期: 2021-09-30

ZTFLH:

R521

基金资助:宁波市省市共建医学重点学科传染病学（2016-S04）

通信作者: 车洋,E-mail：13805876046@163.com

作者简介: 叶静芬,本科,副主任护师,主要从事护理临床和管理工作

引用本文:

叶静芬, 方晴, 胡耀仁, 许小敏, 车洋. 北京基因型耐多药结核分枝杆菌二线抗结核药物耐药基因突变特征分析[J]. 预防医学, 2021, 33(10): 983-987.
YE Jingfen, FANG Qing, HU Yaoren, XU Xiaomin, CHE Yang. Second-line drug resistance associated mutations in multidrug-resistant Mycobacterium tuberculosis Beijing genotype strains. Preventive Medicine, 2021, 33(10): 983-987.

链接本文:

http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2021.10.003 或 http://www.zjyfyxzz.com/CN/Y2021/V33/I10/983

[1] World Health Organization.Global tuberculosis report 2019[R]. Geneva:World Health Organization,2019.
[2] ZUMLA A I,GILLESPIE S H,HOELSCHER M,et al.New antituberculosis drugs,regimens,and adjunct therapies:needs,advances,and future prospects[J].Lancet Infect Dis,2014,14(4):327-340.
[3] PARWATI I,VAN CREVEL R,VAN SOOLINGEN D.Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains[J].Lancet Infect Dis,2010,10(2):103-111.
[4] YANG C G,LUO T,SUN G M,et al.Mycobacterium tuberculosis Beijing strains favor transmission but not drug resistance in China[J].Clin Infect Dis,2012,55(9):1179-1187.
[5] YUAN X L,ZHANG T T,KAWAKAMI K,et al.Genotyping and clinical characteristics of multidrug and extensively drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China[J/OL].BMC Infect Dis(2013-07-12)[2021-09-15].https://link.springer.com/article/10.1186/1471-2334-13-315.
[6] CHEN Q Y,PANG Y,LIANG Q F,et al.Molecular characteristics of MDR Mycobacterium tuberculosis strains isolated in Fujian,China[J].Tuberculosis(Edinb),2014,94(2):159-161.
[7] KENDALL E A,COHEN T,MITNICK C D,et al.Second-line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis:a quantitative perspective[J].Int J Infect Dis,2017,56:185-189.
[8] SHARMA A K,GUPTA N,KALA D K,et al.A study on pattern of resistance to second-line anti tubercular drugs among multi drug resistant tuberculosis patients[J].Indian J Tuberc,2018,65(3):233-236.
[9] 中国防痨协会基础委员会.结核病诊断实验室检验规程[M]. 北京:中国教育文化出版社,2006:49-51.
[10] ABDEL A M,ABIGAIL W.The World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Surveillance for Anti-Tuberculosis Drug Resistance:a model for other infectious diseases[J]. Clin Infect Dis,2005,41(Suppl. 4):S258-S262.
[11] 中国防痨协会.耐药结核病化学治疗指南(2019年简版)[J].中国防痨杂志,2019,41(10):1026-1027.
[12] CHEN J,TSOLAKI A G,SHEN X,et al.Deletion-targeted multiplex PCR(DTM-PCR)for identification of Beijing/W genotypes of Mycobacterium tuberculosis[J].Tuberculosis,2007,87(5):446-449.
[13] 刘海灿,赵丽丽,赵秀芹,等. 耐多药结核分枝杆菌二线药物耐药相关基因分析[J].疾病监测,2016,31(6):471-476.
[14] 郭海萍,尚媛媛. 全基因组测序在结核病分子流行病学研究中的应用[J]. 预防医学,2020,32(9):899-903.
[15] 纪律,刘晓俊,余云芳,等. 宜昌市耐药结核分枝杆菌MIRU-VNTR分子特征及耐药基因突变分析[J]. 预防医学,2021,33(2):149-152.
[16] YUAN X,ZHANG T,KAWAKAMI K,et al.Genotyping and clinical characteristics of multidrug and extensively drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China[J].BMC Infect Dis,2013,13(2):315-318.
[17] OKAMOTO S,TAMARU A,NAKAJIMA C,et al.Loss of a conserved 7-methylguanosine modification in 16S rRNA confers low-level streptomycin resistance in bacteria[J].Mol Microbiol,2007,63(4):1096-1106.
[18] ZHANG Z,LU J,WANG Y,et al.Prevalence and molecular characterization of fluoroquinolone Mycobacterium tuberculosis isolates in China[J].Antimicrob Agents Chemother,2014,58(1):364-369.

[1]	王云霞, 郑娟娟, 张娟娟, 黄佩佩, 梅金周, 袁青. 2011—2018年宝安区肺结核患者耐多药的影响因素分析[J]. 预防医学, 2021, 33(7): 701-703.
[2]	张婷, 刘珊珊, 汪清雅, 张娅, 李建琼, 陈健. 重庆市疾控机构耐药肺结核治疗管理评价指标体系构建[J]. 预防医学, 2021, 33(6): 592-594.
[3]	朱传新, 郑文力, 金聪囡, 苏菲菲, 吴矛矛, 孙宝昌, 张佳峰. 温州市新报告HIV-1感染者治疗前耐药分析[J]. 预防医学, 2021, 33(5): 446-450.
[4]	王小龙, 张梦寒, 朱莉勤, 邹文燕. 苏州市阪崎肠杆菌污染状况调查[J]. 预防医学, 2021, 33(4): 414-417.
[5]	纪律, 刘晓俊, 余云芳, 余枫华, 周攀. 宜昌市耐药结核分枝杆菌MIRU-VNTR分子特征及耐药基因突变分析[J]. 预防医学, 2021, 33(2): 149-152.
[6]	王云霞, 王甜甜, 张娟娟, 陈帆, 龚言红, 曹世义, 卢祖洵, 袁青. 宝安区老年肺结核患者异烟肼和利福平耐药的影响因素分析[J]. 预防医学, 2021, 33(1): 69-71.
[7]	朱业蕾, 潘爱珍, 周琳, 柳正卫, 张明五, 吴坤阳, 王晓萌, 吴蓓蓓. 浙江省非结核分枝杆菌流行状况及耐药性分析[J]. 预防医学, 2021, 33(1): 6-10.
[8]	郭海萍, 尚媛媛, 李姗姗, 逄宇. 全基因组测序在结核病分子流行病学研究中的应用[J]. 预防医学, 2020, 32(9): 899-903.
[9]	周绍英, 张琰, 杨元斌, 高红. 宁波市食源性腹泻病例沙门菌感染分析[J]. 预防医学, 2020, 32(9): 904-906.
[10]	吴跃进, 林冠凯, 章乐怡, 李毅, 楼辉煌, 洪程基, 王良怀, 谢爱蓉, 胡玉琴. 温州市禽肉中空肠弯曲菌检测结果及耐药性分析[J]. 预防医学, 2020, 32(7): 686-688.
[11]	阙凤霞, 钟海明, 蔡光, 刘春甫, 宋灿磊, 叶玉龙. ICU环境分离肺炎克雷伯菌分子分型及耐药性分析[J]. 预防医学, 2020, 32(4): 388-391.
[12]	方芳, 赵丽丽, 徐庆嵩, 宋冰. 呼吸科住院病例医院感染病原菌分布及耐药性分析[J]. 预防医学, 2020, 32(4): 369-372.
[13]	高华强, 卢巧玲, 金法祥, 孟海滨, 孙佳美, 许树红. 绍兴市肺结核患者耐药特征分析[J]. 预防医学, 2020, 32(4): 384-387.
[14]	刘洁楠, 易井萍, 李科峰, 金永富, 戴亚欣, 陈灿. 舟山市白纹伊蚊对拟除虫菊酯类杀虫剂的抗性表型和KDR基因突变分析[J]. 预防医学, 2020, 32(12): 1253-1256.
[15]	朱光平, 薛晨晨, 范宏亮, 吴南翔. 环境中抗生素抗性基因研究进展[J]. 预防医学, 2020, 32(11): 1121-1125.

Viewed

Full text

Abstract

Cited

Shared

Discussed